Novartis CEO says company starting strategic review of Sandoz generic drug unit

Vas Narasimhan, Novartis CEO, joins 'Closing Bell' to discuss the company after reporting earnings. Narasimhan and CNBC's Sara Eisen discuss a wide range of topics; from a strategic review of its generic drug unit, evolving through Covid and where Novartis' strategy goes from here.